Ligand Pharmaceuticals Inc (LGND)
86.06
+1.04
(+1.22%)
USD |
NASDAQ |
May 17, 16:00
86.01
-0.05
(-0.06%)
After-Hours: 20:00
Ligand Pharmaceuticals Gross Profit Margin (Quarterly): 90.70% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 90.70% |
December 31, 2023 | 94.16% |
September 30, 2023 | 89.40% |
June 30, 2023 | 93.67% |
March 31, 2023 | 91.55% |
December 31, 2022 | 57.10% |
September 30, 2022 | 76.10% |
June 30, 2022 | 75.34% |
March 31, 2022 | 87.13% |
December 31, 2021 | 67.51% |
September 30, 2021 | 82.35% |
June 30, 2021 | 63.87% |
March 31, 2021 | 85.22% |
December 31, 2020 | 75.09% |
September 30, 2020 | 84.82% |
June 30, 2020 | 81.55% |
March 31, 2020 | 85.88% |
December 31, 2019 | 92.83% |
September 30, 2019 | 87.31% |
June 30, 2019 | 90.38% |
March 31, 2019 | 91.13% |
December 31, 2018 | 95.04% |
September 30, 2018 | 96.80% |
June 30, 2018 | 98.74% |
March 31, 2018 | 98.60% |
Date | Value |
---|---|
December 31, 2017 | 96.56% |
September 30, 2017 | 92.85% |
June 30, 2017 | 96.77% |
March 31, 2017 | 98.83% |
December 31, 2016 | 92.41% |
September 30, 2016 | 95.38% |
June 30, 2016 | 96.31% |
March 31, 2016 | 96.78% |
December 31, 2015 | 95.83% |
September 30, 2015 | 92.94% |
June 30, 2015 | 85.88% |
March 31, 2015 | 92.64% |
December 31, 2014 | 82.59% |
September 30, 2014 | 90.01% |
June 30, 2014 | 88.82% |
March 31, 2014 | 84.64% |
December 31, 2013 | 91.07% |
September 30, 2013 | 80.48% |
June 30, 2013 | 87.33% |
March 31, 2013 | 94.31% |
December 31, 2012 | 82.93% |
September 30, 2012 | 89.29% |
June 30, 2012 | 92.42% |
March 31, 2012 | 97.25% |
December 31, 2011 | 84.09% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
57.10%
Minimum
Dec 2022
94.16%
Maximum
Dec 2023
82.60%
Average
85.55%
Median
Gross Profit Margin (Quarterly) Benchmarks
ANI Pharmaceuticals Inc | 64.23% |
Annovis Bio Inc | -- |
United Therapeutics Corp | 89.24% |
ADMA Biologics Inc | 47.77% |
Blueprint Medicines Corp | 96.68% |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | 13.82% |
Return on Assets | 11.93% |
Return on Invested Capital | 13.52% |
Operating Margin (Quarterly) | 9.65% |
Return on Net Operating Assets | 18.61% |